Sirtris Pharmaceuticals, Inc. (SIRT) Receives Orphan Drug Designation from FDA for Treatment of MELAS
Sirtris Pharmaceuticals (SIRT), based in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 diabetes. The company’s drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins. Sirtuins are a recently discovered class of enzymes that Sirtris believes control the aging process. The company is also engaged in a human clinical trial for MELAS, a mitochondrial disorder. The company was recently granted…